Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : MGC Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Details : The agreement is for the distribution in key European territories and the UK for CannEpil®, used to treat Drug Resistant Epilepsy, and CogniCann®, used to treat patients with Dementia and Alzheimer's disease.
Brand Name : CannEpil
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 05, 2022
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : MGC Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?